ELDN insider transaction filings
Eledon Pharmaceuticals, Inc. — 28 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen ELDN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Gros David-Alexandre C — Chief Executive Officer, Director | 1 | — | — | 2 |
| Perrin Steven — President, Director | 1 | — | — | 2 |
Recent Form 4 filings — Eledon Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Perrin Steven — President, Director | Grant/award (A): 152,353 @ $0 · Tax withholding (F): 72,138 @ $3.38 | EDGAR |
| 2026-08-04 | 4 | Gros David-Alexandre C — Chief Executive Officer, Director | Grant/award (A): 354,454 @ $0 · Tax withholding (F): 194,791 @ $3.38 | EDGAR |
| 2026-01-16 | 4 | McBride John S. — Director | Option exercise (M): 3,430 @ $0 · Option exercise (M): 3,430 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Hillson Jan — Director | Option exercise (M): 3,430 @ $0 · Option exercise (M): 3,430 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Kirk Allan — Director | Option exercise (M): 3,430 @ $0 · Option exercise (M): 3,430 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Lee June — Director | Option exercise (M): 3,430 @ $0 · Option exercise (M): 3,430 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Robinson James A. Jr. — Director | Option exercise (M): 3,430 @ $0 · Option exercise (M): 3,430 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Katkin Keith — Director | Option exercise (M): 8,575 @ $0 · Option exercise (M): 8,575 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Hillson Jan — Director | Grant/award (A): 30,870 (derivative) @ $0 · Grant/award (A): 3,430 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | McBride John S. — Director | Grant/award (A): 30,870 (derivative) @ $0 · Grant/award (A): 3,430 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Gros David-Alexandre C — Chief Executive Officer, Director | Grant/award (A): 600,000 (derivative) @ $0 · Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Smith Bryan E. — General Counsel, Corporate Sec | Grant/award (A): 150,500 (derivative) @ $0 · Grant/award (A): 64,500 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Robinson James A. Jr. — Director | Grant/award (A): 30,870 (derivative) @ $0 · Grant/award (A): 3,430 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Little Paul Sean — Chief Financial Officer | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Perrin Steven — President, Director | Grant/award (A): 243,000 (derivative) @ $0 · Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Lee June — Director | Grant/award (A): 30,870 (derivative) @ $0 · Grant/award (A): 3,430 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Kirk Allan — Director | Grant/award (A): 30,870 (derivative) @ $0 · Grant/award (A): 3,430 (derivative) @ $0 | EDGAR |
| 2025-01-13 | 4 | Katkin Keith — Director | Grant/award (A): 77,175 (derivative) @ $0 · Grant/award (A): 8,575 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Smith Bryan E. — General Counsel, Corporate Sec | Grant/award (A): 474,350 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Little Paul Sean — Chief Financial Officer | Grant/award (A): 525,032 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Perrin Steven — President, Director | Grant/award (A): 840,438 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Gros David-Alexandre C — Chief Executive Officer, Director | Grant/award (A): 1,015,743 (derivative) @ $0 | EDGAR |
| 2024-10-31 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Purchase (P): 2,213,816 (derivative) @ $3.65 · Purchase (P): 2,100,244 (derivative) @ $3.65 · Purchase (P): 440,489 (derivative) @ $3.65 | EDGAR |
| 2024-06-14 | 4 | Gros David-Alexandre C — Chief Executive Officer, Director | Grant/award (A): 517,454 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Little Paul Sean — Chief Financial Officer | Grant/award (A): 267,470 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Perrin Steven — President, Director | Grant/award (A): 428,148 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Smith Bryan E. — General Counsel, Corporate Sec | Grant/award (A): 241,650 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Purchase (P): 1,031,385 · Purchase (P): 821,121 · Purchase (P): 75,431 · Purchase (P): 3,173,135 (derivative) · Purchase (P): 2,526,238 (derivative) · Purchase (P): 232,068 (derivative) | EDGAR |
Recent 8-K events — Eledon Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ELDN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →